Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

Study Questions:

What is the effect of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibition on levels of low-density lipoprotein cholesterol (LDL-C) in patients on atorvastatin therapy?